Tandem Diabetes Care (NSDQ:TNDM) said today that it enrolled the first patient in an at-home pivotal trial of its t:slim X2 insulin pump combined with the company’s predictive low glucose suspend algorithm.
Using DexCom’s G5 mobile continuous glucose monitor and Tandem’s predictive technology, the insulin pump is designed to halt insulin delivery when it predicts low blood glucose and resume insulin delivery when glucose levels begin to rise.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem launches pivotal trial for predictive insulin pump appeared first on MassDevice.